Through the analysis of the transient expression of the luciferase reporter gene in HeLa cells, an evaluation has been made of the transcriptional activity of oestrogens and of selective oestrogen receptor (ER) modulators (SERMs), mediated by the a and b isoforms of the ER, on the epidermal growth factor receptor gene promoter. Oestrogen-activated ERb presents a lower transcriptional activity compared with ERa, probably due to structural differences in the AF-1 regions of the receptors. Also SERMs induce different responses depending on the receptor isoform bound. Indeed, the phyto-oestrogens, genistein and daidzein, act as weak agonists of the oestrogenic activity via ERa, but as full agonists when bound to ERb. The synthetic SERM 4OH-tamoxifen, on the other hand, displays an opposite behaviour since it exerts a full agonist action through ERa, but acts as a full antagonist via ERb. As we have previously shown for ERa, an ERb/Sp1 functional synergism has also been highlighted, by means of gel mobility shift assays. Moreover, our results show that the sensitivity of target tissues to oestrogens and SERMs can be affected by coexpression of ERs, depending on the formation of appropriate levels of homo-and heterodimers, thus providing a useful approach to predict the effects of hormonal treatment.
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The biological effects of oestrogens are mediated by the oestrogen receptor (ER). In human, two subtypes of ER exist, ERa (Green et al., 1986) and ERb (Mosselman et al., 1996; Enmark et al., 1997) , which display different expressions in specific tissues and organs. The ER subtypes belong to the steroid/thyroid nuclear receptor superfamily, members of which share a common structural architecture (Evans, 1988; Beato, 1989) . They are composed of three independent, but interacting functional domains: the N-terminal domain, the DNA binding domain (DBD) , and the ligand binding domain (LBD) . In particular, the LBDs of ERa and ERb share a high degree of homology in their primary amino-acid sequence and are also very similar in their tertiary architecture (Mosselman et al., 1996; Enmark et al., 1997) . Consequently, several compounds exhibit similar binding properties to the ERs, even if some ligands have been shown to bind preferentially to specific ER subtypes (Kuiper et al., 1998) . ERa and ERb bind specific DNA sequences, called oestrogen response elements (EREs), with similar specificity and affinity, due to the high homology of their DBDs (Truss and Beato, 1993; Mosselman et al., 1996; Enmark et al., 1997) . ERs can modulate the expression of target genes not only through specific binding to the EREs, but also without coming directly into contact with the DNA, by means of functional interactions with other transcription factors, such as Sp1 and the fos/jun complex, that bind to their cognate DNA elements within the promoter of the genes (Paech et al., 1997; Dong et al., 1999, and their refs.; Kim et al., 2003) . In particular, Sp1 has proven critical for full promoter activity of many genes, including ERa (De Graffenried et al., 2002) .
In addition to their role in female reproduction, oestrogens appear to exert beneficial effects on unrelated tissues, as suggested by the results of oestrogen replacement therapy in postmenopausal women. Some reports, in fact, support the hypothesis that oestrogens can prevent osteoporosis, have beneficial effects on the cardiovascular system, decrease the incidence of coronary heart disease and have even been associated with improvement in cognitive function (Manolagas and Kousteni, 2001 , and their references). ER is able to bind several structurally distinct compounds, termed selective ER modulators (SERMs), which have the ability to act both as agonists and antagonists depending on the tissue and the promoter context as well as the ER isoform targeted. One of the first SERMs to be described was tamoxifen, that is, to date, the most widely used antioestrogen for the management of breast cancer, although prolonged treatment increases the risk of endometrial cancer. Thus, tamoxifen behaves as an ER antagonist in the mammary gland and as an agonist in the uterus and bone (Cosman and Lindsay, 1999) . Phyto-oestrogens are a different group of SERMs, the presence of which in the human diet appears to have beneficial effects on health. Indeed, epidemiological studies have shown that in countries in which the incidence of breast, colon and prostate cancer is low, the intake of phyto-oestrogens is significantly higher, suggesting that these compounds may also act as chemopreventive compounds (Kurzer and Xu, 1997) .
A variety of aberrant signal transduction pathways have been implicated in the growth of human tumours. An increased expression of the epidermal growth factor (EGF) receptor (EGFR) gene has been found in a wide range of tumours, indicating a more aggressive behaviour of these cancers compared to those with a low or normal expression (Neal et al., 1985; Yasui et al., 1988) . 17b-Oestradiol (E 2 ) has been shown, both in the rat uterus and in human breast cancer cells, to transiently upregulate EGFR mRNA and protein (Lingham et al., 1988; Yarden et al., 1996) . We have already shown (Salvatori et al., 2000) that this induction depends on the direct transcriptional action of ERa on the EGFR gene, retained by a 36-bp promoter fragment that does not display a canonical ERE. We also revealed that the oestrogenic response was exerted through a DNA binding-independent action of the ERa on the promoter, which involved protein-protein interactions with Sp1.
The role of the E 2 -activated ERb and the effect of both natural and synthetic SERMs, on a transient expression of the luciferase reporter gene directed by the EGFR gene promoter, have now been evaluated by means of the transfection of each ER expression vector in cultured ER-negative HeLa cells from human uterine cervical cancer.
Results

ERb-mediated transactivation on the minimal promoter
To study the effect exerted by oestrogens and SERMs on the transcription of the luciferase reporter gene directed by the EGFR promoter, the construct containing the 1081-bp promoter was cotransfected with the plasmids expressing the two isoforms of the ER in HeLa cells. Treatment with 100 nm E 2 conferred a significant oestrogen-responsiveness to the reporter gene through the activation of the ERa, but not by ERb. Treatment with 1000 nm genistein, 1000 nm daidzein or 100 nm 4OH-tamoxifen, did not induce any EGFR promoter activity, independently of the ER subtype bound (data not shown).
As we reported elsewhere (Salvatori et al., 2000) , the oestrogenic effect mediated by ERa on the 1081-bp EGFR promoter, progressively increased with the reduced length of the promoter, up to a 36-bp (from À112 to À77) fragment which acts as a minimal promoter for the EGFR gene. After treatment with increasing doses of E 2 , also the construct expressing the ERb led to an enhancement in reporter gene transcription directed by the 36-bp EGFR promoter in a dosedependent manner, even if to a lesser extent (from 77 up to 57%) than with the other ER isoform (Figure 1a) .
We also investigated the role, for ERb activity, of the transcription factor Sp1, previously shown to be essential for ERa action in our system (Salvatori et al., 2000) . The ERb expression vector and the construct containing the 36-bp EGFR promoter presenting four point mutations in the binding site of Sp1 (pSVOALD5 0 -36 m) were cotransfected. Data (Figure 1b) show that, after E 2 activation of ERb, the transactivation of the luciferase gene directed by the mutated 36-bp promoter was lower than that due to the normal promoter, and that this effect became more evident at the highest doses of E 2 (up to 37% inhibition of the transcription).
Functional interaction between the ERb and Sp1
The molecular mechanism responsible for the functional interaction between the ERb and Sp1 was studied by P-labelled oligonucleotides, we showed that, although the ERb bind the consensus ERE sequence located in the promoter of the vitellogenin-B1 gene (data not shown), it was not able to bind the imperfect ERE half-site located on the 36-bp EGFR promoter fragment ( Figure 2a , lane 2). The presence of nuclear extracts of HeLa cells resulted in the formation of a retarded band (lane 3), the intensity of which was enhanced after incubation with 2 and 4 pmol of recombinant ERb protein (lanes 3-5), in a dose-dependent manner ( Figure 2b ). The intensity of the retarded band was completely abolished by competition with a 500-fold excess of cold oligonucleotides corresponding to the 36-bp EGFR promoter fragment and to the consensus binding sequence for Sp1 (lanes 7, 9). Furthermore, it was decreased by competition with the unlabelled oligonucleotide corresponding to the 36-bp EGFR promoter fragment with the mutated Sp1 binding site (lane 8), and was not affected by the addition of the cold oligonucleotide containing the consensus ERE sequence (lane 10). These findings demonstrate that the retarded band of lane 3 corresponds to the binding of the EGFR minimal promoter to the Sp1 protein contained in HeLa nuclear extracts. In fact, the addition of anti-Sp1 antibody to the binding reaction produced a supershifted band (lane 6), whereas the addition both of antiERa and anti-ERb antibodies was ineffective (data not shown). The oestrogen-responsiveness of the EGFR promoter was thus retained by the 36-bp fragment despite the lack of a direct contact between ERb and the promoter, due to a molecular mechanism involving an Sp1/DNA interaction.
Transcriptional activity of SERMs mediated by ERa and ERb
The ability of the 36-bp EGFR promoter to direct the transcription of the reporter gene, through the ligandactivated ER isoforms, was also investigated after treatment with SERMs.
The transactivation induced by the phyto-oestrogens genistein and daidzein and by 4OH-tamoxifen was compared to the effect of E 2 , after incubation of ERatransfected cells with concentrations up to 1000 nm of ligand (Figure 3a ). Genistein and daidzein exerted a partial agonistic action (50 and 60%, respectively, compared to the maximum response to E 2 ) only at the higher concentration tested. On the contrary, 4OH-tamoxifen had an effect comparable to that of E 2 , acting as a full agonist of the oestrogenic action. The transcriptional activity of SERMs mediated by the ERb is shown in Figure 3b . Genistein and daidzein, at the highest concentrations, showed agonist activity (up to 90 and 100%, respectively, compared to 100 nm E 2 ), while 4OH-tamoxifen failed to enhance reporter gene transcription, at any dose.
Thus, the modulatory action of genistein, daidzein and 4OH-tamoxifen, in the same cell and promoter context, depends on the ER isoform bound.
Antagonist activity of SERMs on oestrogenic action
Investigating the effects of combined treatment with 10 nm E 2 and 10-to 100-fold excess genistein on the ERa-transfected HeLa cell cultures, it was seen that the effect was comparable to that exerted by E 2 alone (data not shown), both at the lower dose of genistein, that, when supplemented alone was ineffective in promoting gene expression, and at the higher dose, that alone showed a 50% reduced oestrogen-like effect.
On the contrary, antagonist activity was found when cell cultures were transfected with the 36-bp EGFRluciferase construct and the ERb expression vector, and The intensity of the bands produced in the presence of nuclear extracts and increasing amounts of ERb protein was calculated densitometrically and expressed as fold induction7s.e. with respect to the intensity of the band corresponding to the Sp1 protein alone, which was set at 1 treated with 10 nm E 2 plus 10-or 100-fold excess 4OH-tamoxifen (Figure 4) , since increasing concentrations of the SERM induced a progressive competitive inhibition of the transcriptional effect of E 2 .
ER a/b expression ratio affects ligand action
The effects of the two ERs, that, as shown, are not functionally equivalent, have been studied by means of cotransfection of HeLa cell cultures with a fixed amount (5 mg) of the plasmid expressing one ER isoform and increasing amounts (2.5-20 mg). of the other subtype expression vector (Figure 5a ). Cells were treated with E 2 Figure 3 Transactivation induced by SERMs depends on ER isoform bound. HeLa cells were cotransfected with the 36-bp EGFR promoter-luciferase construct and 5 mg ERa (a) or ERb (b) expression plasmids. Increasing concentrations of E 2 , genistein (G), daidzein (D) and 4OH-tamoxifen (4OH-T) were added to the cells. Transcriptional activity of ERa and ERb was measured, and values were expressed as fold induction7s.e., where the reporter activity, in the absence of hormone treatment, was arbitrarily set at 1. Each set of transfections was performed at least three times in duplicate Figure 4 4OH-tamoxifen (4OH-T) acts as antagonist via ERb. HeLa cells, cotransfected with the minimal EGFR promoterreporter gene construct and 5 mg ERb expression plasmid, were treated with 100 and 1000 nm 4OH-T, alone or in combination with 10 nm E 2 . Data are reported as fold induction7s.e., with respect to untreated control cells, and represent experiments performed in duplicate at least three times Figure 5 Coexpression of ER subtypes affects cell-responsiveness to ligands. HeLa cells were cotransfected with the 36-bp EGFR promoter-reporter construct, a fixed amount (5 mg) of the plasmid expressing one ER isoform and increasing amounts (2.5-5-10-20 mg) of the other subtype expression vector. E 2 (a) or 4OH-tamoxifen (4OH-T) (b) were added to cell cultures and the resulting luciferase expression was measured. Data are presented as the mean7s.e. of the ratio between treated and untreated control samples. At least three experiments were carried out for each treatment group concentrations (10 and 100 nm) at which both receptors displayed the maximum transcriptional activity. Increasing amounts of ERb caused inhibition of ERa activity (up to 76 and 59%), confirming that ERb/ERb homodimers might be less active. When equal amounts of ERb expression vector and increasing amounts of ERa-construct were cotransfected, E 2 treatment led to strong enhancement of reporter gene transactivation to higher levels (up to 150 and 182%) than those obtained by ERa alone.
We then investigated the role of the coexpression of the two ERs on 4OH-tamoxifen agonist/antagonist activity. The effect of 1000 nm 4OH-tamoxifen on HeLa cell cultures, cotransfected, in turn, with 5 mg of one ER isoform and increasing amounts (2.5-20 mg) of the other expression vector, is shown in Figure 5b . In the presence of an excess of ERb, that, when ligand-bound was unable to mediate a transcriptional action, a reduction up to 54% of the effect mediated by the ERa alone was observed. On the other hand, an excess of ERa, by means of which the ligand induced high levels of transcription, resulted in an enhancement up to 187% of the transactivation mediated by the ERb alone. These findings suggest, therefore, that the effect of oestrogens and antioestrogens on target tissues strongly depends upon the relative expression ratio of ERa and ERb.
Discussion
In human breast cancer cell lines and in the rat uterus, the EGFR gene is transcriptionally activated in response to E 2 , producing a transient upregulation of EGFR mRNA and protein (Lingham et al., 1988; Yarden et al., 1996) . Both tissues express ERa and ERb Kuiper et al., 1997) , suggesting that the transcriptional effect observed could result from the interaction between the two ER subtypes. In a previous study, we showed that the EGFR gene transcription is mediated by the E 2 -activated ERa through a DNA bindingindependent pathway (Salvatori et al., 2000) . These findings led us to evaluate, in the present study, the role exerted by the b isoform of the ER and by the ERa/ERb coexpression, on the oestrogen and SERM-induced transactivation of the EGFR gene, in the transiently transfected HeLa cells.
The expression of the reporter gene directed by the full-length EGFR promoter, after cotransfection of the constructs expressing the two ER subtypes, was significantly enhanced by E 2 via the ERa, but not via the ERb, while it was unaffected by genistein, daidzein and 4OH-tamoxifen. As previously shown for ERa (Salvatori et al., 2000) , a considerable oestrogendependent gene expression was revealed when ERb transcriptional ability was tested on the minimal promoter (Figure 1a) . On the other hand, ERb shows a lower transcriptional activity compared to that of ERa, which could reflect structural differences between the ER isoforms and different recruitment of coactivators and corepressors. The reduced transcriptional activity of the full length, with respect to the minimal, EGFR promoter, caused by E 2 -activated ERa and ERb, could reflect the different expression of a reporter gene in various cell lines, as also shown by others (Saville et al., 2000) , suggesting that ER action is dependent upon the specific cell context. The ERb, that in vitro experiments have shown to interact with Sp1 (Saville et al., 2000) , enhances, in a concentration-dependent manner (Figure 2 ), Sp1-DNA interactions on the GC-rich region located in the minimal EGFR promoter, in the same manner as ERa (Salvatori et al., 2000) . The formation of a ternary complex DNA/Sp1/ERb was not revealed, as the addition of the specific antibody did not show the presence of the ERb protein in the retarded bands highlighted in lanes 4 and 5. Nevertheless, the interaction between ERb and Sp1 proteins exerts a functional activity, as the E 2 -induced expression of the luciferase gene, directed by the 36-bp EGFR promoter that presents an impaired Sp1 binding site (Hudson et al., 1990b) , displays inhibition up to 37% of the transactivation directed by the wild-type minimal promoter (Figure 1b) , also showing the relevance of the Sp1 binding sequence for ERb-mediated transactivation.
Despite the expectations when considering the higher binding affinity for ERb with respect to ERa (30-fold), genistein induces a luciferase expression, directed by the minimal EGFR promoter, acting as an agonist via both ERs (Figure 3a, b) . On the other hand, differences in binding affinity are not always correlated with the transactivation mediated by the ligand-bound receptor (Sun et al., 1999) , as further revealed by our observations on daidzein transcriptional efficacy (Figure 3a ,b) compared to its negligible affinity to both ER subtypes. Nevertheless, in the presence of genistein, ERb is more efficient in recruiting coactivators than ERa (Routledge et al., 2000; Bramlett et al., 2001) , thus offering a possible explanation for the greater ability of ERb to enhance reporter gene activity (Figure 3a, b) , and E 2 -bound ERa shows a greater ability to recruit coactivators than the genistein-bound ERa (Bramlett et al., 2001) , consistent with the weaker effect of genistein on the transactivation mediated by this receptor (Figure 3a) . Further confirmation stems from our data (not shown) that, in the presence of a marked excess of genistein, no modulatory action was revealed on E 2 -induced transactivation via ERa. It is, therefore, clear that specific effects may be associated with distinct changes in the tertiary structure of ERa and ERb following ligand binding, and with selective coactivator recruitment, in specific cell and promoter contexts. 4OH-tamoxifen is the only compound that, in our system, presents an opposite behaviour, since it acts as an agonist via the ERa, but as an antagonist through the ERb (Figure  3a,b) . The differences in transcriptional response to 4OH-tamoxifen, and the strong competitive effect over oestrogen activity exerted via ERb by an excess of compound (Figure 4) , could depend on structural differences in the amino-termini of the receptors, as ERb AF-1 lacks the region that mediates the agonist action of 4OH-tamoxifen through ERa (McInerney et al., 1998).
Since ligand-activated ERa and ERb mediate different transcriptional effects, the responsiveness of target tissues to oestrogenic compounds may differ depending on the relative expression levels of the two receptor isoforms. In fact, we showed that an E 2 -induced expression of the 36-bp EGFR-luciferase construct mediated by ERa/Sp1 interactions was reduced as a consequence of the coexpression of ERb, whereas the lower transcriptional activity induced via the ERb/Sp1 complex increased in the presence of ERa (Figure 5a ). In accordance with our results, it has been proposed that ERb homodimers have the highest affinity for corepressors and/or the lowest affinity for coactivators, and consequently are less active (Hall and McDonnell, 1999) . Intriguingly, we observed that the weaker receptor appears to cause overactivity of ERa, when the latter is present in large amounts (Figure 5a ). This increased transactivation cannot be due to an excess of receptors, since the transfection of 5 mg ERa expression vector triggered the maximum E 2 -induced reporter activity (Salvatori et al., 2000) , but could be the result of the formation of appropriate levels of heterodimers between the two ER subtypes, that mediate oestrogenic effects through synergic activity, as shown also by others in a different system (Van den Wijngaard et al., 2000) . The finding that ERb can decrease the sensitivity of ERa-expressing cells to E 2 , and that the ERa expression in ERb-positive cells results in the dramatic enhancement of E 2 -induced effects, could be of great importance in those cancer tissues where ERs colocalize, to evaluate the true effects of hormonal treatment. Furthermore, excess of ERa restored the responsiveness to 4OH-tamoxifen blocked by ERb, whereas higher levels of ERb suppressed the agonist activity exerted by the ligand via ERa (Figure 5b ). These observations, which show that also the sensitivity of a target tissue to antioestrogens can be affected by ERs coexpression, suggest that ERb-positive tumours might show a better response to the drug. On the other hand, according to our findings on 4OH-tamoxifen-induced transactivation, the adult uterus, which is a major oestrogen target tissue and on which tamoxifen behaves as an ER agonist, was found to have a very low expression of ERb compared with that of ERa (Weihua et al., 2000) .
The effect of the two ER isoforms on the transcriptional regulation of the EGFR gene, could be a crucial point in mediating the activity of oestrogens and SERMs in normal and neoplastic target tissues. Therefore, further studies on normal breast and uterine cells, and in the different phases of the neoplastic progression, could lead to the definition of tissue-and cell-specificity in order to assess the clinical importance of the model proposed here, with a view to predicting the response to therapy.
Materials and methods
Plasmids and reagents
The 1081-bp (À1100 to À19 bp, oriented to the ATG translation start site as position þ 1) 5 0 region of the EGFR gene, cloned into the pSVOALD5 0 luciferase expression vector (De Wet et al., 1987; Hudson et al., 1989) , was kindly provided by Gordon Gill (Department of Medicine, University of California-San Diego, USA). The wild-type and mutant 36-bp (À112 to À77 bp) regions of the promoter, cloned into the luciferase expression vector at the HindIII site to give the pSVOALD5 0 -36 and pSVOALD5 0 -36 m constructs, respectively, have been described elsewhere (Salvatori et al., 2000) . The human ERa and the 485 aa human ERb, each cloned into the pSG5 expression vector (Tora et al., 1989; Enmark et al., 1997) , were kindly provided by Pierre Chambon (CNRS, Strasbourg, France) and Jan-Ake Gustafsson (Department of Medical Nutrition, Karolinska Institute, Huddinge, Sweden), respectively.
Recombinant human Sp1 and ERb proteins were purchased from Promega and PanVera (Madison, WI, USA), respectively. Anti-Sp1 (1C6) and anti-ERa (C-314) monoclonal antibodies, and anti-ERb (L-20) polyclonal antibody were obtained from Santa Cruz Biotech (Santa Cruz, CA, USA). Ethanol was used as solvent for E 2 , genistein and 4OH-tamoxifen, while DMSO was used for daidzein.
Structures of the oligonucleotides synthesized by Biogen (Rome, Italy) are listed below. The consensus ERE and the imperfect ERE half-site on the X. laevis vitellogenin B1 and the 36-bp EGFR promoters, respectively, are underlined; the Sp1 binding sites, on the consensus Sp1 and the EGFR core promoter oligonucleotides, are shown in bold script, and every mutated base of the Sp1 sequence on the EGFR minimal promoter (36-bp EGFR-mut) is indicated with an asterisk. 36-bp EGFR promoter: 
Cell cultures and transient cotransfection assays
HeLa cells were routinely maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 1% antibiotics, 1% glutamine, 3.5 g/l glucose and 5% foetal bovine serum (FBS) in an air-carbon dioxide (95 : 5) atmosphere 371C. Cells were grown in phenol-red free DMEM dextran-charcoal-stripped FBS (DCCFBS) 4 days before transfection. Using the calcium phosphate method, 8 mg of EGFR gene promoter-derived constructs, 2.5-20 mg ERa and/or ERb expression vectors and 6 mg b-galactosidase plasmid were cotransfected. The empty vector pSG5 was used as a control, and to maintain uniform levels of added DNA. Background was determined by transfection of the promoterless pSVOALD5 0 luciferase plasmid. Trypsinized cells, suspended in 5% DCCFBS medium containing the calcium phosphate DNA precipitate, were plated in a 10 cm tissue culture dish. After 2 h, cultures were treated with either E 2 , genistein, daidzein, 4OH-tamoxifen, ethanol or DMSO (0.01% total volume). At 20 h after transfection, the medium was changed to DMEM containing 2.5% DCCFBS, and hormone treatment was continued for a further 24 h (Hudson et al., 1990a) . Cells were then scraped from the plates, and protein extracts were prepared (Ausubel et al., 1995) . The luciferase expression was measured on an LB 9506 luminometer (EG&G Berthold, Bundoora, VIC, Australia), adding 80 ml cell extract to 20 ml of a 5 Â luciferase assay reaction mix containing 10 mm KH 2 PO 4 (pH 7.75), 50 mm MgSO 4 , 33mm DTT, 0.6 mm ATP, 0.3 mm acetyl CoA and 0.5 mm luciferin. b-Galactosidase activity was also assayed: 100 ml of cell extract was added to 100 ml of Onitrophenyl-b-d-galactopyranoside (4 mg/ml in 100 mm sodium phosphate pH 7.5) and to 400 ml of 60mm Na 2 HPO 4 , 40mm NaH 2 PO 4 , 10 mm KCl, 1 mm MgSO 4 , 38 mm b-mercaptoethanol. Optical density (OD) was measured at 420 nm (Maniatis et al., 1982) . Data were normalized as light units of luciferase activity per unit of b-galactosidase activity to correct for differences in transfection efficiency between samples, and are presented as fold induction, where the activity of the EGFR promoter construct in the absence of hormone treatment was arbitrarily set at 1. Each data point is the average7s.e. of at least three separate experiments performed in duplicate.
Electrophoretic mobility shift assays
Single-strand oligonucleotides containing the EGFR promoter sequence between positions (À112 to À77 bp) were annealed and labelled at the 5 0 end using T4-polynucleotide kinase and [g-32 P]ATP. Then 2 mg nuclear extract (Schreiber et al., 1989) , 2-4 pmol ERb protein and 1 mg poly (dI-dC) were preincubated for 20 min at 41C in an appropriate binding buffer (5% glycerol, 1 mm MgCl 2 , 0.5 mm DTT, 10 mm HEPES pH 7.9, 50 mg/ml BSA) in the presence of 10 nm E 2 . The mixture was then incubated for a further 30 min at room temperature with 0.6 ng of (20 000 c.p.m.) 32 P-EGFR minimal promoter oligonucleotide. In supershift experiments, 2 mg of anti-Sp1, anti-ERa and antiERb antibodies were added during preincubation. For competition experiments, 500-fold molar excess cold oligonucleotides, containing the consensus Sp1, the consensus ERE, the wild-type or mutant EGFR core promoter sequences, were added to the binding mixture 20 min before addition of the 32 P-labelled probe. Samples were loaded onto a 4% polyacrylamide gel (acrylamide-bisacrylamide ratio, 37.5 : 1) and run for 1 h 45 min at 170 V in 0.25 Â TBE. Gels were then dried, and protein-DNA binding was visualized by autoradiography.
